- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04957901
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Mature B Cell Non-Hodgkins Lymphoma (NHL).
September 19, 2023 updated by: Yizhuo Zhang, Sun Yat-sen University
The next-generation sequencing (NGS) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors.
The tumor tissue (FFPE) and plasma samples from the newly diagnosed pediatric mature B-NHL patients were collected and sequenced by 475 genes panel before, during and post treatment, to evaluate the significance of the ctDNA in efficacy prediction, predicting recurrence or mechanism of resistance to chemotherapy for pediatric mature B-NHL.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, observational cohort study.
Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol.
The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
Collection and analysis the results of ctDNA and chemotherapy response, to explore the mutation map of pediatric mature B-NHL and to evaluate the significance of liquid biopsy for efficacy prediction, predicting recurrence, mechanism of resistance to chemotherapy.
Study Type
Observational
Enrollment (Estimated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yizhuo Zhang
- Phone Number: 02087342460
- Email: zhangyzh@sysucc.org.cn
Study Locations
-
-
-
Guangzhou, China
- Recruiting
- Yizhuo Zhang
-
Contact:
- Yizhuo Zhang
- Phone Number: 87342460
- Email: zhangyzh@sysucc.org.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Asian population predominates
Description
Inclusion Criteria:
- Children with mature B-cell lymphoma (BL, DLBCL, high-grade B-cell lymphoma, mediastinal large B-cell lymphoma) that met the criteria and required treatment upon histological and pathological diagnosis;
- Age: < 18 years old;
- The working status of the Eastern Cooperative Oncology Group (ECOG) (PS) : 0-2 points;
- CT/MRI measurable lesion was defined as the longest diameter of at least 1 lymph node ≥ 1.5cm, and it was clearly measurable in 2 vertical directions;
- Complete clinical laboratory examination and pathological examination information;
- Patients can be evaluated on time, and the required samples can be obtained throughout the testing process;
- After the patient is informed of the project, the informed consent signed by the patient or his legal representative is obtained.
Exclusion Criteria:
Patients with any of the following items will not be enrolled in this study:
- Incomplete baseline samples (preoperative plasma samples, tissue, bone marrow, cerebrospinal fluid) due to various reasons;
- The follow-up samples cannot be obtained during the monitoring process;
- The researcher considered it unsuitable for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The mutation rate of the ctDNA of pediatric mature B-NHL
Time Frame: From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yizhuo Zhang, Sun Yat-sen University CancerCenter
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2021
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
July 5, 2021
First Submitted That Met QC Criteria
July 9, 2021
First Posted (Actual)
July 12, 2021
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 19, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- cDNA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-hodgkin Lymphoma
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on modified BFM-95 protocol
-
Sun Yat-sen UniversityCompletedChildhood Non-Hodgkin's Lymphoma
-
Israeli Medical AssociationRecruitingHigh-Risk Cancer | Philadelphia-Negative ALLIsrael
-
Boston University Charles River CampusUniversity of Kentucky; Harvard School of Public Health (HSPH)RecruitingDepressive Disorder | Anxiety DisordersUnited States
-
Imam Abdulrahman Bin Faisal UniversityActive, not recruitingBirth Weight | Preterm | Feeding Disorder NeonatalSaudi Arabia
-
Tuğba AtanCompletedCoronary Artery DiseaseTurkey
-
University of Sao PauloCompletedContracture of Elbow JointBrazil
-
Clalit Health ServicesCompleted
-
University of AlcalaCompletedVascular Diseases | Lipedema | Dermatologic Complication | AssessmentSpain
-
Universidade Cidade de Sao PauloTerminatedPatellar TendinopathyBrazil
-
University Medical Centre LjubljanaActive, not recruitingPulmonary Vein IsolationSlovenia